Staying current with pharmacology updates is essential for diabetes educators preparing for the Certified Diabetes Educator (CDE) exam. Recent advancements in diabetes medication have improved patient outcomes and expanded treatment options. This article highlights key updates to help educators and students stay informed, covering new drug classes, revised clinical guidelines, and emerging strategies that directly affect the exam blueprint and daily practice.

New Medication Classes and Approvals

In the past five years, the U.S. Food and Drug Administration (FDA) has approved several novel agents that expand the therapeutic arsenal against type 2 diabetes (T2D). The most significant addition is the dual GIP/GLP-1 receptor agonist class, which targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The first-in-class drug, tirzepatide (Mounjaro), has demonstrated superior glycemic control and weight reduction compared to selective GLP-1 agonists in the SURPASS and SURMOUNT trials. For the CDE exam, candidates should understand that tirzepatide is administered once weekly via subcutaneous injection and is approved for T2D (and more recently for obesity under the brand name Zepbound). Its mechanism includes enhanced insulin secretion, suppressed glucagon release, and delayed gastric emptying, with an additional effect on appetite centers in the brain.

Fixed-Dose Combinations

The FDA has also approved new fixed-dose combination products that simplify regimens. One example is insulin glargine/lixisenatide (Soliqua 100/33) and insulin degludec/liraglutide (Xultophy 100/3.6). These dual-acting injectables combine a long-acting basal insulin with a GLP-1 receptor agonist, addressing both fasting and prandial hyperglycemia while reducing the risk of hypoglycemia and supporting weight loss. For the CDE exam, educators need to know the indications, dosing considerations (e.g., starting dose, titration), and the importance of patient education on injection technique and storage.

Oral Formulations of Injectable Drugs

Another emerging trend is the development of oral versions of traditionally injectable peptides. Oral semaglutide (Rybelsus) is the first GLP-1 receptor agonist available in an oral tablet. It utilizes a unique absorption enhancer (SNAC) to facilitate gastrointestinal uptake. CDE candidates should be aware of specific administration instructions: it must be taken on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before the first food or other medication of the day. The efficacy and side effect profile are similar to injectable semaglutide, though gastrointestinal tolerability may differ.

Updated Pharmacological Guidelines from Major Organizations

The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have updated their consensus reports, emphasizing a patient-centered approach that considers comorbidities, cost, and patient preferences. The 2024 ADA Standards of Care now include a stronger recommendation for using GLP-1 receptor agonists or SGLT2 inhibitors as first-line add-on therapy to metformin in patients with established cardiovascular disease, heart failure, or chronic kidney disease, regardless of baseline HbA1c. Additionally, for patients with obesity, glucose-lowering agents that promote weight loss are preferred.

Key guideline updates relevant to the CDE exam include:

  • Cardiovascular risk reduction: SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) and GLP-1 RAs (e.g., liraglutide, semaglutide) have shown cardiovascular benefit in outcomes trials; they are now recommended for patients with ASCVD, HF, or CKD.
  • Weight management: Medications supporting ≥5% weight loss (e.g., high-dose semaglutide, tirzepatide) are prioritized for patients with BMI ≥27 kg/m².
  • Individualized glycemic targets: Less stringent goals (HbA1c <8%) are acceptable for patients with limited life expectancy or advanced complications; therapy should be de-escalated to avoid overtreatment.
  • Deprescribing: In older adults with type 1 or type 2 diabetes, sulfonylureas and insulin may be de-escalated if hypoglycemia is frequent; newer agents with lower hypoglycemia risk are preferred.

For comprehensive study, refer to the ADA's Pharmacologic Approaches to Glycemic Treatment and the 2024 ADA/EASD consensus report.

Emerging Pharmacological Strategies on the Horizon

Beyond currently marketed drugs, several novel mechanisms are in late-stage development. CDE exam candidates should be familiar with these trends, as they may appear in scenario-based questions.

Combination Therapies Targeting Multiple Pathways

Dual and triple agonists that combine actions at GLP-1, GIP, and glucagon receptors are undergoing clinical trials. The aim is to amplify glycemic control and weight loss while minimizing side effects. For example, retatrutide (a triple agonist) has shown mean weight loss >24% in obesity trials. Although not yet approved, educators should understand the rationale: modulating multiple incretin pathways can produce synergistic effects on insulin secretion, appetite suppression, and energy expenditure.

Insulin Sensitizers and Non-Insulin Analogues

Selective peroxisome proliferator-activated receptor (PPAR) modulators are being developed to improve insulin sensitivity without the side effects of older thiazolidinediones. Additionally, novel small molecules that mimic glucokinase activation are under investigation. These agents may become part of future combination therapies, especially for patients with predominant insulin resistance.

Long-Acting Injectable Formulations

The trend toward less frequent dosing continues. Once-weekly basal insulins such as insulin icodec (currently in regulatory review) and once-weekly GLP-1/GIP co-agonists are expected to simplify regimens. Research also explores monthly or bimonthly formulations of semaglutide. CDE candidates should appreciate the impact on adherence and the need for proper dose adjustment when switching from daily or weekly regimens.

Oral Biologics and New Delivery Systems

Advances in oral peptide delivery (e.g., using permeation enhancers like SNAC, or mucoadhesive polymers) may allow oral versions of insulin and other injectables. While still preclinical for insulin, the success of oral semaglutide has spurred development. Educators should be aware of the potential for expanded options but also of ongoing limitations such as low oral bioavailability and strict administration precautions.

Implications for Diabetes Educators and CDE Exam Preparation

The CDE exam (now the Certified Diabetes Care and Education Specialist, CDCES) places strong emphasis on pharmacology knowledge. According to the most recent exam content outline, up to 25% of questions relate to pharmacologic therapies. Staying current with updates is therefore critical for candidates.

What to Focus On

  • New drug names and classes: Know both generic and brand names (e.g., tirzepatide/Mounjaro, oral semaglutide/Rybelsus, dulaglutide/Trulicity). Recognize that some names are used for both diabetes and weight loss indications (e.g., semaglutide as Ozempic vs. Wegovy).
  • Mechanisms of action: Differentiate between SGLT2 inhibitors (block glucose reabsorption in kidney), GLP-1 RAs (stimulate insulin, suppress glucagon, slow gastric emptying), and dual agonists (additional GIP activity). Understand how these affect glucose, weight, and cardiovascular outcomes.
  • Side effect profiles: Common adverse effects include gastrointestinal upset with GLP-1 RAs, genital mycotic infections with SGLT2 inhibitors, and injection site reactions. For the exam, know serious adverse events: pancreatitis, diabetic ketoacidosis with SGLT2 inhibitors (especially in type 1), and thyroid C-cell tumors in rodents (contraindication in patients with personal or family history of medullary thyroid carcinoma).
  • Monitoring and safety: Recognize the need to check renal function before starting SGLT2 inhibitors (eGFR >30 mL/min/1.73 m² generally required), and hepatic function for certain medications. Also be aware of drug–drug interactions, such as the effect of insulin secretagogues on hypoglycemia risk when combined with GLP-1 RAs or insulin.
  • Role in type 1 diabetes: While most new agents are approved for type 2, off-label or adjunctive use is sometimes considered. For example, pramlintide is approved as an adjunct to insulin in type 1; SGLT2 inhibitors have a limited indication in type 1 but require strict patient selection to avoid DKA.

Educational Strategies for Patients

Diabetes educators play a crucial role in translating pharmacology updates into actionable patient education. Key teaching points include:

  • Medication adherence: Explain the benefit of simplified dosing (e.g., once-weekly agents) and how to set up reminders.
  • Injection technique: For injectable agents, demonstrate proper injection site rotation (abdomen, thigh, upper arm), needle disposal, and safe storage.
  • Managing side effects: Advise patients starting GLP-1 RAs to take with food, start at low dose, and titrate gradually. For SGLT2 inhibitors, educate on genital hygiene and signs of euglycemic DKA (nausea, vomiting, abdominal pain despite normal glucose).
  • Hypoglycemia awareness: Emphasize that newer agents with low hypoglycemia risk do not eliminate the need for self-monitoring, especially when used with insulin or sulfonylureas.
  • Cost and access: Discuss insurance coverage, copay assistance programs, and biosimilar alternatives when available.

Collaboration with Healthcare Providers

Educators often serve as the bridge between patient and prescriber. Staying abreast of updates enables meaningful input into treatment decisions. For instance, when a patient with heart failure is not achieving glycemic targets, the educator can suggest considering an SGLT2 inhibitor based on current guidelines. Similarly, for a patient with overweight/obesity, a GLP-1 receptor agonist or tirzepatide may be recommended.

Practical Study Tips for the CDE Exam

To incorporate these pharmacology updates into your preparation:

  • Use official resources: The ADA Standards of Care (published annually) is a primary source. Focus on Section 9 (Pharmacologic Approaches to Glycemic Treatment) and the cardiovascular/kidney sections.
  • Create comparison charts: Make a table listing drug classes, examples, mechanisms, indications, side effects, and contraindications. This will help with rapid recall.
  • Review landmark trials: Know the key outcomes of major trials (e.g., EMPA-REG OUTCOMES for empagliflozin, LEADER for liraglutide, REWIND for dulaglutide, SURPASS for tirzepatide).
  • Practice scenario questions: Use question banks that include new agents. For example: "A patient with T2D, established atherosclerotic cardiovascular disease, and an HbA1c of 8.5% on metformin. Which agent is most appropriate to add?" Answer: GLP-1 RA or SGLT2 inhibitor.
  • Attend webinars and read updates: The Association of Diabetes Care & Education Specialists (ADCES) offers pharmacology updates and review courses.
  • Revisit FDA approvals: Check the FDA Drug News for Diabetes periodically to stay current on new approvals and label changes.

Conclusion

The landscape of diabetes pharmacotherapy is evolving rapidly. For CDE exam candidates and practicing educators, mastering these updates is not just a test requirement but a clinical necessity. Understanding new drug classes like dual GIP/GLP-1 agonists, emerging oral formulations, and guideline-driven individualized therapy will equip educators to support patients in achieving better outcomes. By staying informed through official resources and integrating this knowledge into education and collaboration, diabetes care professionals can maintain the highest standard of current care.

For additional depth, read the 2024 ADA/EASD consensus report and the ADA Scientific Sessions for the latest developments.